2025 Asia-Pacific Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report
Description
The 2025 Asia-Pacific Cell And Gene Therapy Manufacturing Services Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in the Asia-Pacific region are WuXi AppTec, Thermo Fisher Scientific, Charles River Laboratories, and Lonza. WuXi AppTec, headquartered in China, has significant manufacturing facilities in Shanghai and Singapore, offering GMP manufacturing, process development, viral vector production, and regulatory support specifically targeting Asia-Pacific clients. Thermo Fisher Scientific expanded its presence by opening a Cell Therapy Collaboration Centre in Singapore, supporting development from clinical research to commercial manufacturing. Charles River Laboratories and Lonza are also key players with a strong global presence, engaging in cell and gene therapy manufacturing services that cater to the growing market in Asia-Pacific.
These companies benefit from the rapid growth of the Asia-Pacific cell and gene therapy market, which accounted for over 21% of global revenue in 2023 and is projected to grow at a fastest CAGR due to rising clinical trials, government investments, and regulatory advancements in countries like China, Japan, South Korea, and India. The demand for scalable manufacturing services, including GMP-compliant production and advanced quality controls such as PCR-based techniques, further drives their participation. These firms are leveraging strategic partnerships, facility expansions, and local regulatory pathways to strengthen their foothold in this rapidly emerging market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell and Gene Therapy Manufacturing Services Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cell and Gene Therapy Manufacturing Services Market in the Asia-Pacific region are WuXi AppTec, Thermo Fisher Scientific, Charles River Laboratories, and Lonza. WuXi AppTec, headquartered in China, has significant manufacturing facilities in Shanghai and Singapore, offering GMP manufacturing, process development, viral vector production, and regulatory support specifically targeting Asia-Pacific clients. Thermo Fisher Scientific expanded its presence by opening a Cell Therapy Collaboration Centre in Singapore, supporting development from clinical research to commercial manufacturing. Charles River Laboratories and Lonza are also key players with a strong global presence, engaging in cell and gene therapy manufacturing services that cater to the growing market in Asia-Pacific.
These companies benefit from the rapid growth of the Asia-Pacific cell and gene therapy market, which accounted for over 21% of global revenue in 2023 and is projected to grow at a fastest CAGR due to rising clinical trials, government investments, and regulatory advancements in countries like China, Japan, South Korea, and India. The demand for scalable manufacturing services, including GMP-compliant production and advanced quality controls such as PCR-based techniques, further drives their participation. These firms are leveraging strategic partnerships, facility expansions, and local regulatory pathways to strengthen their foothold in this rapidly emerging market.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
